retatrutide safety clinical trials retatrutide ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Demand for Unapproved Weight-Loss Drug

The expanded label now includes its use in adolescents 12 years or older, with an initial body mass index (BMI) at or above the 95th percentile for age and sex

Retatrutides GI effects can cause fluid losses through diarrhea or vomiting

December 20 Product: Zealands glepaglutide Indication: Short bowel syndrome The FDA on Thursday shot down Zealand Pharmas aspirations to use its investigational GLP-2 analog glepaglutide for the treatment of short bowel syndrome

Cataneo et al., 2019

Rather, they make it easier to eat less by changing the hunger and appetite signals running in the background while the medication is active